InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-41.0%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Lochner Daniel, Chief Financial Officer. Insider active across 3 companies, notably Oyster Point Pharma, Inc.. Cumulatively, 12 reports have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €350k. Activity tracked since 28 July 2021. The latest transaction was disclosed on 4 March 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Lochner Daniel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
26,500 shares0Common StockSEC:0001791187-26-000005:0
6,000 shares@ US$21.6127.9% of flowCommon StockSEC:0001791187-26-000003:0
Canonical exit: 11 May 2026 (T+90)
2,077 shares@ US$23.2210.4% of flowCommon StockSEC:0001791187-26-000002:0
5,430 shares0Common StockSEC:0001791187-25-000003:0
4,617 shares@ US$54.14100.0% of flowCommon StockSEC:0001415889-25-003350:0
Canonical exit: 6 May 2025 (T+90)
18,074 shares0Common StockSEC:0001415889-25-003227:0
938 shares@ US$11.701.9% of flowCommon StockSEC:0001209191-23-001073:0
3,258 shares@ US$11.206.9% of flowCommon StockSEC:0001209191-22-059938:0
19,500 shares0Common StockSEC:0001209191-22-002978:0
8,590 shares@ US$11.5131.0% of flowCommon StockSEC:0001209191-21-062476:0
7,500 shares@ US$11.5126.3% of flowCommon StockSEC:0001209191-21-054919:0
7,500 shares@ US$11.5126.4% of flowCommon StockSEC:0001209191-21-048517:0
12 of 12 declarations
About Lochner Daniel
Lochner Daniel is Chief Financial Officer. He has 12 filings in total, and across the 12 sampled filings the purchases total EUR 349902 with no sales, over the period from 2021-07-29 to 2026-03-05. The main filings concern Tectonic Therapeutic, Inc. and Oyster Point Pharma, Inc., with the modal transaction nature listed as Attribution.
